LinkMed logo
sp
sp divider
The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.
COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology
MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.
OlerupIntl

Olerup SSP AB

Verksamhet: Olerup SSP AB is world leading in the development of kits for genomic HLA typing, a required step prior to a transplantation to match the donor and recipient. The better the match the lower the risk of complications following transplantation. HLA typing is a standard procedure prior to bone marrow transplantations (he-matopathic stem cell transplantations) but is also used in conjunction with organ transplantations (kidney, lung, heart, etc.) Olerup SSP AB was established in 1992 by assistant professor Olle Olerup and has 23 employees.

Sektor: Diagnostik och medicinteknik

Terapiområde: Transplantation

VD: Olle Olerup

Ordförande: Ingemar Lagerlöf

Venture manager: Ingemar Lagerlöf

Ownership stake: 100,0%

Address: Olerup SPP AB
Hasselstigen 1
133 33 Saltsjöbaden

www.olerupssp.se

Back